<DOC>
	<DOC>NCT00436293</DOC>
	<brief_summary>Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin. Secondary objective: To assess tumor control and survival</brief_summary>
	<brief_title>Taxotere + Cisplatin in Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>International Union against Cancer stages III and IV newly diagnosed NPC Inadequate bone marrow reserve Inadequate renal function Other primary malignancy Evidence of distant metastases The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>